Department of Oncology, Geneva University Hospital, Geneva, Switzerland; Swiss Cancer Center Leman (SCCL), University of Geneva, Lausanne, Switzerland.
Hospital Universitario de Navarra (HUN), Medical Oncology Department, Pamplona, Spain; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
ESMO Open. 2022 Apr;7(2):100392. doi: 10.1016/j.esmoop.2022.100392. Epub 2022 Feb 16.
There has been no major change of practice in gastrointestinal oncology at the European Society for Medical Oncology (ESMO) symposium 2021, but confirmation that immunotherapy in combination with chemotherapy has become standard of care in several indications. The European Organisation for Research and Treatment of Cancer (EORTC) Gastrointestinal Track Cancer Group has selected important phase II and III trials presented during the symposium across all gastrointestinal cancers as well as early reports on new drugs or new combinations that may change practice in the future.
在 2021 年欧洲肿瘤内科学会（ESMO）研讨会上，胃肠肿瘤学的实践并没有重大改变，但免疫疗法联合化疗已在多个适应证中成为标准治疗方法得到确认。欧洲癌症研究与治疗组织（EORTC）胃肠癌研究组选择了研讨会上所有胃肠癌相关的重要 II 期和 III 期试验以及新药物或新联合用药的早期报告，这些研究或药物可能会改变未来的实践。
